Renal vasodilatory action of dopamine in patients with heart failure: Magnitude of effect and site of action

Circulation

Volumn 117, Issue 2, 2008, Pages 200-205

  Elkayam, Uri ^a,b   Ng, Tien M H ^a   Hatamizadeh, Parta ^a   Janmohamed, Munir ^a   Mehra, Anilkumar ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

Blood flow; Heart failure; Inotropic agents; Kidney; Pharmacology; Vasodilation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; DIURETIC AGENT; DOPAMINE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; METOCLOPRAMIDE; NITRATE;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; FEMALE; HEART FAILURE; HEART OUTPUT; HUMAN; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; VASODILATATION;

EID: 38049160214     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.737106     Document Type: Article

References (31)

1. Haewood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004;9:195-201.
2. Shlipak MG, Massie B. The clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514-1517.
3. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.
4. Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger AJ, Elkayam U. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol. 2004;94:957-960.
5. Cody RJ, Junkman S, Covet AB, Kubo SH, Sealy JE, Pondolfino K, Clark M, James G, Laragh JH. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int. 1988;34:361-367.
6. Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery E, Fisher ML, Rao K, Gottlieb SS. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620-1625.
7. Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshani M. Intravenous nitroglycerin in the treatment of decompensated heart failure; potential benefits and limitations. J Cardiovasc Pharmacol Ther. 2004;9:227-241.
8. Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. Am J Cardiol. 1988;62:86E-93E.
9. Petein M, Heppner B, Bache RJ, Cohn JN, Pierpont GL. Hemodynamic and regional blood flow response to piroximone (MDL 19,205) in dogs with congestive heart failure: a comparison with dobutamine. J Pharmacol Exp Ther. 1987;241:956-960.
10. Leier CV, Bambach D, Thompson MJ, Cattaneo SM, Goldberg RJ, Unverferth DV. Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure. Am J Cardiol. 1981;48:1115-1123.
11. Lee MR. Dopamine and the kidney: ten years on. Clin Sci. 1993;84:357-375.
12. D'Orio V, el Allaf D, Juchmes J, Marcelle R. The use of low doses of dopamine in intensive care medicine. Arch Int Physiol Biochim. 1984;92:S11-S20.
13. Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med. 1994;22:1919-1925.
14. Ungar A, Fumagalli S, Marini M, Di Serio C, Tarantini F, Boncinelli L, Baldereschi G, Valoti P, La Cava G, Olianti C, Masotti G, Marchionni N. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit Care Med. 2004;32:1125-1129.
15. Doucette JW, Corl PD, Payne HM, Flynn AE, Goto M, Nassi M, Segal J. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85:1899-1911.
16. Elkayam U, Cohen G, Gogia H, Mehra A, Johnson JV, Chandraratna PA. Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. J Am Coll Cardiol. 1996;28:176-182.
17. Elkayam U, Mehra A, Cohen G, Tummala PP, Karaalp IS, Wani OR, Canetti M. Renal circulatory effects of adenosine in patients with chronic heart failure. J Am Coll Cardiol. 1998;32:211-215.
18. Nishioka T, Amanullah AM, Luo H, Berglund H, Kim CJ, Nagai T, Hakamata N, Katsushika S, Uehata A, Takase B, Isojima K, Berman DS, Siegel RJ. Clinical validation of intravascular ultrasound imaging for assessment of coronary stenosis severity: comparison with stress myocardial perfusion imaging. J Am Coll Cardiol. 1999;33:1870-1878.
19. Lim MJ, Kern MJ. Coronary pathophysiology in the cardiac catheterization laboratory. Curr Probl Cardiol. 2006;8:493-550.
20. Savader SJ, Lund GB, Osterman FA Jr. Volumetric evaluation of blood flow in normal renal arteries with a Doppler flow wire: a feasibility study. J Vasc Interv Radiol. 1997;8:209-214.
21. Paliotti R, Ciulla MM, Buonamici V, Barelli M, Morganti A, Magrini F. Intravascular Doppler technique for monitoring renal venous blood flow in man: comparative study. J Nephrol. 2003;16:57-62.
22. Beregi JP, Mounier-Vehier C, Willoteaux S, Gautier C, Lions C, Gaxotte V. Intravascular Doppler for the evaluation of renal blood flow: validation and demonstration of vessel reactivity [in French]. J Mal Vasc. 2000;25:336-342.
23. Mounier-Vehier C, Cocheteux B, Haulon S, Devos P, Lions C, Gautier C, Carre A, Beregi JP. Changes in renal blood flow reserve after angioplasty of renal artery stenosis in hypertensive patients. Kidney Int. 2004;65:245-250.
24. McDonald RH Jr, Goldberg LI, McNay JL, Tuttle EP Jr. Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest. 1964;43:1116-1124.
25. Beregovich J, Bianchi C, Rubler S, Lomnitz E, Cagin N, Levitt B. Dose-related hemodynamic and renal effects of dopamine in congestive heart failure. Am Heart J. 1974;87:550-557.
26. Goldberg LI, Rajfer SI. Dopamine receptors: applications in clinical cardiology. Circulation. 1985;72:245-248.
27. Smit AJ, Meijer S, Wesseling H, Donker AJ, Reitsma WD. Effect of metoclopramide on dopamine-induced changes in renal function in healthy controls and in patients with renal disease. Clin Sci. 1988;75:421-428.
28. Israel R, O'Mara V, Austin B, Bellucci A, Meyer BR. Metoclopramide decreases renal plasma flow. Clin Pharmacol Ther. 1986;39:261-264.
29. Cockrill BA. Renal-dose dopamine: a siren song? Lancet. 1994;344:7-8.
30. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153:98-104.
31. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64.